On March 16, the Antimicrobial Drugs Advisory Committee recommended the FDA approve Paxlovid, a drug that has been available under an emergency use authorization for more than a year. LeadingAge submitted comments on March 9 to the committee and FDA in support of approval, highlighting provider experiences and ongoing needs for safe and effective COVID-19 mitigations.